Tirzepatide reduces the predicted risk of developing type 2 diabetes in people with obesity or overweight: Post hoc analysis of the SURMOUNT-1 trial.

Emily R HankoskyHui WangLisa M NeffHong KanFangyu WangNadia N AhmadAdam StefanskiW Timothy Garvey

Published in: Diabetes, obesity & metabolism (2023)

Tirzepatide treatment significantly reduced the 10-year predicted risk of developing T2D compared with placebo in participants with obesity or overweight, regardless of baseline glycaemic status.

Keyphrases

type diabetes
weight loss
weight gain
insulin resistance
glycemic control
metabolic syndrome
phase iii
high fat diet induced
physical activity
body mass index
clinical trial
study protocol
phase ii
skeletal muscle